← Leaderboards
Rajesh Krishnan
Oncternal Therapeutics, Inc.
$2,834,010
Attributed
$2,834,010
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2022–24$2M$1.5M$1M$500K$0
'22
'23
'24
Funding mix
By agency
NIH$2,834,010 · 2
By mechanism
R44$2,834,010 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Dose”
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$13,673,728
Research focus
DoseIn VitroPre-ClinicalToxic EffectOralInvestigational New Drug ApplicationIn VivoPharmaceutical PreparationsProteinsToxicologyPre-Clinical ModelBiological AvailabilityMedicalAndrogen SensitiveAwardFundingAdvanced Prostate CancerExperimental StudyFormulationGeneticDrug CandidateDrug DevelopmentAndrogen ReceptorAndrogenic
Grant awards (4)
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease$1,007,034
R44 · FY2024 · NS · contact PI
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as New Potential Therapeutic for Kennedy's Disease$50,000
R44 · FY2024 · NS · contact PI
Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease$753,745
R44 · FY2023 · NS · contact PI
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development$1,023,231
R44 · FY2022 · CA · contact PI